Evidence mapPaperPMID 40765487Full record

ArticlePharmaceutical statistics

Target Aggregate Data Adjustment Method for Transportability Analysis Utilizing Summary-Level Data From the Target Population.

Yichen Yan, Quang Vuong, Rebecca K Metcalfe, Tianyu Guan, Haolun Shi, Jay J H Park

Registry-linked trialAbstract read
In one paragraph

Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00981058 (A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00981058 phase3completednot on this map

A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorEli Lilly and CompanyRan2010 to 2024Enrolled1,093ConditionsNon Small Cell Lung CancerArmsNecitumumab, Gemcitabine, Cisplatin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yichen YanDepartment of Statistical and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Quang VuongCore Clinical Sciences, Vancouver, British Columbia, Canada.
Rebecca K MetcalfeCore Clinical Sciences, Vancouver, British Columbia, Canada.
Tianyu GuanDepartment of Mathematics and Statistics, York University, North York, Ontario, Canada.
Haolun ShiDepartment of Statistical and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Jay J H ParkCore Clinical Sciences, Vancouver, British Columbia, Canada.ORCID 0000-0001-5454-014X

Funding

Canadian Statistical Sciences InstituteMitacsNatural Sciences and Engineering Research Council of Canada RGPIN-02963
6 · The paper itself

Abstract

Transportability analysis is a causal inference framework used to evaluate the external validity of studies by transporting treatment effects from a study sample to an external target population by adjusting for differences in the distributions of their effect modifiers. Most existing methods require individual patient-level data (IPD) for both the source and the target population, narrowing its applicability when only target aggregate-level data (AgD) are available. For survival analysis, accounting for censoring may be needed to reduce bias, yet AgD-based transportability methods in the presence of informative-censoring remain underexplored. Here, we propose a two-stage weighting framework named "Target Aggregate Data Adjustment" (TADA) that can simultaneously adjust for both censoring bias and distributional imbalances of effect modifiers. In our framework, the final weights are the product of the time-varying inverse probability of censoring weights and participation weights derived using the method of moments. We have conducted an extensive simulation study to evaluate TADA's performance. We have applied our methods to a real case study on the squamous non-small-cell lung cancer trial (NCT00981058). Our results indicate that TADA can effectively control the bias resulting from moderate censoring representative of most practical scenarios, and enhance the application and clinical interpretability of transportability analyses in settings with limited data availability.

Indexed as

Research DesignBiasCarcinoma, Non-Small-Cell LungClinical Trials, Phase III as TopicComputer SimulationData Interpretation, StatisticalHumansLung NeoplasmsModels, StatisticalMulticenter Studies as TopicRandomized Controlled Trials as TopicSurvival Analysisaggregate‐level datacausal inferenceinverse probability of censoring weightsmethod of momentssurvival analysistransportability analysis

Identifiers

PMID40765487
PMCPMC12326296

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.